Share chart Indivior PLC
Extended chart
Simple chart
About
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. More details| Цена ао | 8.71 |
|---|---|
| Выручка | 0.785 |
| EBITDA | 0.23 |
| Число акций ао | 0.13653 млрд |
| P/E | 0.5628 |
| P/S | 0.0961 |
| P/BV | 0.3608 |
| ISIN | GB00BN4HT335 |
| Сайт | https://www.indivior.com |
| Див.доход ао | 12.24 |
| Дивиденд ао | 0.475 |
| Валюта | usd |
| IPO date | 2014-12-29 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| EV/EBITDA | -2.95 |
| Change price per day: | +0.1149% (8.7) |
|---|---|
| Change price per week: | +10.25% (7.9) |
| Change price per month: | -8.12% (9.48) |
| Change price per 3 month: | -19.94% (10.88) |
| Change price per half year: | -49.86% (17.37) |
| Change price per year: | -57.3% (20.4) |
| Change price per 3 year: | +1 309.39% (0.618) |
| Change price per 5 year: | +6 683.49% (0.1284) |
| Change price per year to date: | -49.39% (17.21) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Two Seas Capital LP | 13670312 | 9.96 |
| Scopia Capital Management LP | 8311367 | 6.06 |
| Vanguard Group Inc | 5846354 | 4.26 |
| Goldman Sachs Group Inc | 5683038 | 4.14 |
| FMR, LLC | 5498087 | 4.01 |
| Artemis Investment Management LLP | 3127399 | 2.28 |
| Bank of America Corporation | 2701855 | 1.97 |
| Polar Capital Holdings PLC | 2621150 | 1.91 |
| Acadian Asset Management. LLC | 2281179 | 1.66 |
| Liontrust Investment Partners LLP | 1995889 | 1.45 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Mark Crossley | CEO & Executive Director | 2.34M | |
| Mr. Ryan Preblick | CFO & Executive Director | 1.14M | |
| Dr. Christian Heidbreder | Chief Scientific Officer | N/A | |
| Mr. Jason Thompson | Vice President of Investor Relations | N/A | |
| Ms. Cynthia Cetani | Chief Integrity & Compliance Officer | N/A | |
| Mr. Jeffrey W. Burris | Chief Legal Officer | N/A | 1972 (52 years) |
| Mr. Jon Fogle | Chief Human Resources Officer | N/A | |
| Mr. Richard Simkin | Chief Commercial Officer | N/A | |
| Mr. Hillel West | Chief Manufacturing & Supply Officer | N/A | |
| Mr. Vishal Kalia | SVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy Officer | N/A |
Address: United States, North Chesterfield. VA, 10710 Midlothian Turnpike - open in Google maps, open in Yandex maps
Website: https://www.indivior.com
Website: https://www.indivior.com
